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Omalizumab is an add-on therapy for patients with uncontrolled severe allergic asthma. In Eur-
ope, patients must fulfil a number of additional criteria to become eligible for omalizumab
therapy, creating a challenge for epidemiology studies to quantify the potential patient pool.
Thus, and in the absence of robust data, the number of omalizumab-eligible patients has re-
mained unclear.
To assess eligible patient numbers, a chart-audit design approach was employed to measure
epidemiology variables based on patient-level data. 770 patient charts were reviewed in desig-
nated towns in Germany and Italy, in collaboration with >200 primary care physicians (PCPs)
and respiratory specialists (RS). This study sample represents >50% and >70% of local RS in
these designated towns of Germany and Italy, respectively.
Of patient charts evaluated, 4 patients were currently receiving omalizumab. A further 31
patients (12 PCP; 19 RS) were evaluated as omalizumab-eligible (i.e. fulfilled all product la-
bel criteria) but were not receiving the drug. Extrapolating to a national level, this yields
>6500 eligible patients in Germany, and >3200 in Italy. Furthermore, this study sample re-
vealed a significant number of PCPs treating uncontrolled severe asthma patients without
referral to RS; these patients are not consistently evaluated for FEV1, aero-allergen sensi-
tivity, a qualitative understanding of severe exacerbations, and day and night-time symp-
toms.Respiratory Diseases, DIMI, Department of Internal Medicine, University of IRCCS San Martino, Largo
. Tel.: þ39 010 555 4890.
(G.W. Canonica).
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Omalizumab eligibility in Italy and Germany 51This study suggests that significant numbers of omalizumab-naı¨ve severe allergic asthma
patients in Germany/Italy are eligible for omalizumab therapy. Despite proven benefits in
uncontrolled severe allergic asthma, adjunctive omalizumab therapy is underutilized.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
It has been estimated that approximately 300 million peo-
ple worldwide have asthma, resulting in a high burden of
morbidity and mortality [1,2]. Although mild and moderate
asthma can usually be controlled with inhaled corticoste-
roids (ICSs) and, if necessary, long-acting b2-agonists
(LABAs), many patients with severe asthma remain inade-
quately controlled [1,3].
The overall prevalence of asthma in Europe has been
estimated to range from 5 to 18%, with approximately 20%
to 30% of these patients having severe asthma [1,2]. An
estimated 20% of patients with severe asthma have inade-
quately controlled disease [4]. In Europe, the prevalence of
uncontrolled asthma among patients receiving ICSs has
been estimated to range from 20 to 67% [5].
Options for patients who require additional therapy
alongside an ICS and LABA include omalizumab, a human-
ized anti-immunoglobulin E (IgE) monoclonal antibody
which is approved in the European Union (EU) as an add-on
therapy for selected patients with uncontrolled severe
persistent allergic asthma [6]. Omalizumab has a well-
established efficacy and safety profile in patients with
inadequately controlled severe allergic asthma [7e13].
Patients in Europe must fulfil a number of additional
criteria to become eligible for omalizumab therapy. In
particular, patients must have severe, persistent, allergic
asthma with baseline IgE concentrations and bodyweights
that fall within the limits set out in the approved asthma
dosing tables for omalizumab. Patients must also have
inadequately controlled asthma despite treatment with an
ICS and LABA. Although the overall burden of asthma in
Europe has been evaluated in several studies [5,14,15],
epidemiological studies have not, to date, provided robust
data to quantify the potential population of severe allergic
asthma patients with unmet needs who could potentially
benefit from omalizumab treatment.
To address this lack of information, we employed a
retrospective medical record-audit approach to measure
epidemiology variables based on patient-level data to
assess the number of patients who could potentially benefit
from omalizumab treatment (“omalizumab-eligible pa-
tients”) in Italy and Germany.Methods
To identify patients potentially eligible for omalizumab
treatment we analysed retail and hospital sales data of
high-dose ICS/LABA within regions of Italy and Germany. A
potential candidate for omalizumab would be receiving
treatment with high-dose ICS/LABA combination, therefore
high-dose ICS/LABA was used as a surrogate to identify
these patients.Region selection
A region in a country consisted of a number of territorial
divisions: in Germany a territorial division was a grouping of
pharmacies (nanobrick) and their surrounding territories; in
Italy the divisions were based on local health authorities
(these definitions are national healthcare subdivisions and
territorial breakdown units of the health ministry in Italy,
and of the sick funds in Germany).
To identify ‘extremes’ of prescribing habits, the retail
and hospital sales of high-dose ICS/LABA products were
first deciled in each country and then the two sets of sales
data (retail and hospital) were matched together by the
territories in each country. Two regions were subse-
quently selected in Italy and Germany to represent two
“extremes” of prescribing dynamics in asthma patients.
For the first extreme, a region in each country was
selected that fell into the top three deciles for retail sales
but the bottom three deciles for hospital sales: this rep-
resented a region with high-prescribing primary care
physicians (PCPs) (based on high retail and low hospital
sales of ICS/LABA) indicating that a high proportion of
patients (on high-dose ICS/LABA) were cared for in the
primary care setting rather than under the care of a res-
piratory or hospital specialist: referral to a respiratory or
hospital specialist was low. For the second extreme, a
region in each country was selected that fell into the
bottom three deciles for retail sales but the top three
deciles for hospital sales: this represented a region with
high-prescribing respiratory or hospital specialists (based
on low retail and high hospital sales of ICS/LABA) indi-
cating that a high proportion of patients (on high-dose
ICS/LABA) were under the care of a respiratory or hospital
specialist rather than in a primary care setting: referral to
a respiratory specialist or hospital was high.
To illustrate that the regions chosen in each country
were representative of the extreme situations, high-dose
ICS/LABA sales were analysed for each country including all
their territorial divisions. In Italy, one region was in the
North West (Piacenza) and one region was in the centre of
the country (Pescara), each with a total population of at
least 250,000. High-prescribing PCP numbers were normal-
ised per head of population; high-prescribing hospital
specialist numbers were normalised per number of hospital
beds. In Germany, one region combined two administrative
districts in Hessen and Brandenburg (Giessen and Cottbus/
Frankfurt an der Oder); the second region combined three
administrative districts in Nordrhein-Westfalen (Reckling-
hausen/Lu¨nen-Kamen/Hamm); each had a population of at
least 850,000.
The regions were also selected according to the
following criteria and with the same normalisation pro-
cedures applied as in Italy, namely per head of population
in the territorial division for the office-based prescriptions
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use of high-dose ICS/LABA combinations in hospital and
office-based settings; 2) sufficient population size to recruit
the required number of physicians; and 3) isolation from
major cities to reduce likelihood of patients migrating to
hospitals in a nearby larger town.Patient selection
Physicians in each region were then recruited if they were
involved in the treatment of allergic asthma and saw at
least five patients per month. Face-to-face interviews were
conducted with office- and hospital-based respiratory spe-
cialists in each region as well as with PCPs and paediatri-
cians (Germany only).
Each PCP/paediatrician had to provide information
during a 1-h interview on allergic asthma patients seen by
them during the previous 3 months. Patients had to be
being treated with a medium- or high-dose ICS in mono-
therapy or in fixed combination with a LABA, to be
included; approximately five patient medical records were
completed per physician interview.
As respiratory specialists were more likely to see a
greater number of allergic asthma patients than PCPs or
paediatricians, a longer interview time was granted to
allow the physician to provide a greater number of patient
medical records. Included patients had persistent, moder-
ate or severe asthma with a year-long aero-allergy, and
were being treated with a medium- or high-dose ICS in
monotherapy or in fixed combination with a LABA, and had
been seen by the physician in the past 3 months.
The medical records completed by each participating
physician were reviewed by the data collection agency (IMS
Health) to ensure relevant diagnostic criteria to identify
patients who were eligible for treatment with omalizumab
had been correctly captured (Fig. 1).
Physicians’ perceptions of a patient’s asthma severity
and control were captured during the interview using showFigure 1 Screening of patient medical records for omalizumab e
agonist; FEV1 Z forced expiratory volume in 1 s; IgE Z immunoglocards. Levels of asthma control were defined according to
the latest GINA guidelines [16]. Participating physicians
were also asked to provide information on their prescribing
and referral practices for each patient with a completed
medical record. In Italy, it was assumed that a patient could
access 11 hospitals across the two regions, therefore data
on prescribing dynamics are based on the number of hos-
pital scripts, and are not physician specific; in Germany,
data are physician-specific due to fewer numbers of
treating physicians across the two regions.
In order to determine the total population eligible for
omalizumab in each country, the number of eligible pa-
tients per region was calculated based on the proportion of
physicians interviewed vs. the total number of physicians in
each region (split by speciality).
The estimated total number of omalizumab-eligible pa-
tients in each region was extrapolated based on the pro-
portion of high-dose ICS/LABA sales in each region (by
speciality) vs. the total high-dose ICS/LABA sales. The
number of omalizumab-treated patients in each region was
then extrapolated following the same methodology, based
on total proportion of omalizumab sales in each region over
the total omalizumab sales.
Results
Identification of omalizumab-eligible patients
A total of 203 face-to-face interviews were conducted with
both PCPs and respiratory specialists; 95 interviews in Italy
and 108 interviews in Germany. In Italy, 78 of the physicians
interviewed were PCPs, seven were office-based pulmo-
nologists and 10 were hospital-based physicians. These
physicians represented 16.7% of PCPs in the selected areas,
70.0% of office-based pulmonologists and 90.9% of hospital-
based physicians. In Germany, 64 of the physicians inter-
viewed were PCPs, 17 were office-based pulmonologists,
nine were paediatricians and 18 were hospital-basedligibility. ICS Z inhaled corticosteroid; LABA Z long-acting b2-
bulin E; RAST test Z radioallergosorbent test.
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the selected areas, 5.3% of paediatricians, 53.1% of office-
based pulmonologists and 30.5% of hospital-based physi-
cians. It was estimated that the study sample represents
>70% and >50% of office-based pulmonologists in the
designated regions of Italy and Germany, respectively.
Medical records from 771 patients were reviewed: 235
patient medical records in Italy and 536 patient medical
records in Germany. All patients had moderate or severe
asthma with aero-allergen sensitivity. Overall, 115/235
(49%) patients and 147/536 (27%) patients in Italy and
Germany, respectively, were receiving treatment with
high-dose ICS and a LABA (Table 1).
When all screening filters are applied to the medical
records, a total of 31 omalizumab-eligible patients were
identified who had not previously received omalizumab: 14
(12%) in Italy and 17 (12%) in Germany (Table 1). An addi-
tional nine patients (two in Italy, seven in Germany) were
currently receiving omalizumab, and five had been previ-
ously treated with omalizumab, but had discontinued.
Key reasons for non-identification of omalizumab-
eligible patients
Lack of adequate testing
Overall, only 95/262 patients (36%) on high-dose ICS/LABA
were documented to have received all three diagnostic
tests (Table 2). In Italy, PCPs’ level of testing was low, with
85% of high ICS/LABA patients not receiving tests for FEV1,
skin-prick/radioallergosorbent test (RAST) and IgE; a
greater percentage of patients (69%) receiving all three
tests were treated by hospital physicians. Similarly in
Germany, a greater percentage of patients treated by
hospital physicians received all three tests compared with
patients being treated by physicians in other settings.Table 1 Omalizumab-eligible patients identified in Italy
and Germany.
Italian
patients N (%)
German
patients N (%)
High-dose ICSa þ LABA 115 (100) 147 (100)
FEV1<80%
b 54 (47) 96 (65)
2 day or night-time
symptoms/weekb
33 (29) 83 (56)
2 exacerbations
in past yearb
27 (23) 54 (37)
Received skin
prick/RASTb
21 (18) 45 (31)
Received IgE testb 20 (17) 33 (22)
IgE 30e1500 IU/mLb 14 (12) 17 (12)
Total 14 (12) 17 (12)
ICS Z inhaled corticosteroid; LABA Z long-acting b2-agonist;
FEV1 Z forced expiratory volume in 1 s; IgE Z immunoglobulin
E; RAST test Z radioallergosorbent test.
a In Italy, due to the very low proportion of patients on high-
dose ICS þ LABA (felt not to reflect the true proportion of pa-
tients receiving high doses) patients receiving medium and high-
dose ICS þ LABA were classed as ‘High-dose’.
b Number meeting criterion for that row and all previous rows.The majority of asthma patients on high-dose ICS/LABA in
all settings are perceived to be partly or fully controlled
106/115 (92%) and 127/147 (86%) patients in Italy and
Germany, respectively, who were receiving high-dose ICS/
LABA treatment for severe allergic asthma were perceived
by physicians as being controlled or partly controlled (Table
3). However, despite the majority of patients being
perceived to be controlled or partly controlled, most pa-
tients were still experiencing exacerbations and daytime
symptoms, indicating that these patients were not
adequately controlled on their current therapy (Fig. 2).
Furthermore, the percentage of patients in Italy experi-
encing exacerbations was high, regardless of whether they
were perceived by physicians as being controlled, partly
controlled, or uncontrolled. Some of these patients may
have been eligible for omalizumab therapy, but were not
receiving the treatment.
Differing prescribing and referral practices in Italy and
Germany (based on physician interviews)
In Italy, omalizumab is a hospital product only; it can only
be prescribed in a public hospital by a specialist physician.
Omalizumab cannot be prescribed by PCPs or office-based
specialists. Of the 14 patients who were eligible for
treatment with omalizumab but who did not receive it,
three were cared for by a PCP (although only 1 autono-
mously by a PCP) and three by office-based pulmonolo-
gists, one of whom refused treatment; the remaining eight
patients were under the care of hospital specialists. Many
patients are not considered for omalizumab because they
remain in the care of PCPs and office-based pulmonolo-
gists, rather than being referred to hospital specialists.
PCPs are less aware of therapy options than office-based
pulmonologists; however, office-based pulmonologists are
still not fully aware of the additional treatment options
available to hospital specialists only. PCPs were most
likely to refer patients to a specialist, with 44% and 51%
stating that they would refer cases of moderate persistent
and severe persistent asthma, respectively. Half of PCPs
stated they would refer patients with moderate/severe
asthma if they knew that specialist centres had more
therapy options; only 16% of PCPs were aware of omali-
zumab. Office-based pulmonologists were least likely to
refer patients (14% would refer patients with severe
persistent asthma), while hospital-based physicians also
referred relatively few patients (10% and 30% would refer
patients with moderate and severe persistent asthma,
respectively).
In Germany, omalizumab can be prescribed in both
hospital (private and public) and office-based settings by all
physicians, pending budgetary approval. Of the 17 patients
who were eligible for treatment with omalizumab but who
did not receive it, 11 were managed by PCPs/paediatri-
cians, 2 by office-based pulmonologists and 4 by hospital-
based physicians. The majority of omalizumab-eligible pa-
tients identified are managed by PCPs. Similarly to Italy,
PCPs are less aware of therapy options than office-based
pulmonologists. PCPs/paediatricians were most likely to
refer patients to a specialist, with 49% stating that they
would refer cases of moderate or severe persistent asthma.
Office-based pulmonologists were less likely to refer pa-
tients, with 12% referring patients with moderate or severe
Table 2 Number (%) of patients documented to be tested for eligibility to receive omalizumab in Italy and Germany.
Italy, N (%) Germany, N (%)
PCPs Office-based
pulmonologists
Hospital
physicians
Total in
Italian
regions
PCPs and
paediatricians
Office-based
pulmonologists
Hospital
physicians
Total in
German
regions
No. of patients
in each setting
79 10 26 115 100 26 21 147
FEV1 tested
a 30 (38) 5 (50) 19 (73) 54 (47) 60 (60) 16 (62) 20 (95) 96 (65)
Skinprick/RAST testeda 54 (68) 8 (80) 25 (96) 87 (76) 84 (84) 19 (73) 13 (62) 116 (79)
IgE testeda 43 (54) 8 (80) 24 (92) 75 (65) 56 (56) 16 (62) 15 (71) 87 (59)
All three tests 12 (15) 4 (40) 18 (69) 34 (30) 40 (40) 9 (34) 12 (57) 61 (41)
FEV1Z forced expiratory volume in 1 s; IgEZ immunoglobulin E; RAST testZ radioallergosorbent test; PCPZ primary care physician.
FEV1, skinprick/RAST, and IgE tests were not documented in all patient medical records; base used in calculations includes all patients
medical records collected.
a Numbers reflect patients who were tested and had results that fulfilled omalizumab eligibility criteria for the particular test.
54 R. Buhl et al.persistent asthma. Similarly, 17% of hospital-based physi-
cians would refer patients with moderate or severe
persistent asthma.
Extrapolation of results from designated regions in
Italy and Germany
Analysis of the total high-dose ICS/LABA sales (including
all regions in Italy and Germany) showed that the two
regions chosen within the two countries were represen-
tative of the overall national situation. Further, total
severe allergic asthma populations in these regions were
not significantly different from the normal population
distribution in these regions. To estimate the total num-
ber of omalizumab-eligible patients, data from each re-
gion (representative sample of patients treated with
high-dose ICS/LABA) was extrapolated to a national
level by using projection factors relating to the physician
and patient populations. This extrapolation yielded
>3200 and >6500 omalizumab-eligible patients in Italy
and Germany, respectively. These eligible patients were
in addition to those already receiving treatment with
omalizumab.Table 3 Physician perception of patient response to current th
Proportion of patients by
Too soon to say
Italy
PCPs 1
Office-based pulmonologists e
Hospital physicians e
Total in Italian regions 1
Germany
PCPs and paediatricians e
Office-based pulmonologists e
Hospital physicians e
Total in German regions
PCPs Z primary care physicians.Discussion
European labelling for omalizumab specifies that severe
allergic asthma patients who remain uncontrolled despite
treatment with ICS and a LABA must meet several specific
criteria in order to be eligible for treatment; there is,
however, a paucity of data describing the population of
patients eligible for treatment with omalizumab in Europe.
To address this current lack of information, we used a
medical record-audit approach using patient-level data to
characterize the number of omalizumab-eligible patients in
Italy and Germany.
From a review of 771 patients’ medical records in
this study, 31 patients (14 patients in Italy; 17 patients in
Germany) were identified who fulfilled all eligibility criteria
for omalizumab treatment, but who were not currently
receiving the therapy. However, there may be a number of
key reasons for non-identification of omalizumab-eligible
patients among this population of severe asthma patients.
Firstly, approximately two-thirds of patients on high-dose
ICS/LABA did not receive all three diagnostic tests (FEV1,
IgE, skin prick/RAST) to assess their eligibility for omali-
zumab treatment. Increasing diagnostic testing for severeerapy in Italy (N Z 115) and Germany (N Z 147).
level of asthma control (%)
Uncontrolled Partly controlled Controlled
9 57 33
0 80 20
4 62 35
7 60 32
16 46 38
8 46 46
10 67 24
14 49 37
Figure 2 Level of asthma control perceived by physician and
percentage of patients receiving oral corticosteroids, experi-
encing exacerbations, hospitalizations or symptoms.
Omalizumab eligibility in Italy and Germany 55asthmatics who remain uncontrolled on high-dose ICS/LABA
may identify additional omalizumab-eligible patients who
may benefit from treatment. In addition, PCPs and office-
based pulmonologists often do not refer patients to
hospital-based pulmonologists as they are less aware of
additional treatment options available. Approximately half
of the PCPs would refer patients with moderate or severe
persistent asthma, and office-based pulmonologists were
less likely to refer (12e14% would refer patients with
moderate or severe asthma). A large number of potential
omalizumab-eligible patients may therefore remain in the
care of PCPs, where they are less likely to receive appro-
priate tests and assessments. It should also be noted that in
Italy, omalizumab is a hospital product only and can only be
prescribed in a public hospital by a specialist physician.
Many patients are therefore not considered for omalizumab
because they remain in the care of PCPs and office-based
pulmonologists, rather than being referred to specialists.
Further research is required to understand the reasons
why PCPs and office-based pulmonologists do not refer
patients to hospital physicians, and also to raise
awareness of alternative adjunctive treatments that may
prove beneficial to patients with severe asthma. A high
number of patients perceived by physicians to be controlled
or partly controlled were still experiencing exacerbations
and daytime symptoms, indicating that these patients were
not adequately controlled on their current therapy.Furthermore, physicians may determine the level of asthma
control in different ways, and this may not always correlate
with the level of symptoms experienced by patients. There
does not appear to be a comparable understanding or
definition of control among physicians; control may there-
fore be defined differently in Italy and Germany. In this
audit, the frequencies of exacerbations and hospitaliza-
tions were high, even in patients regarded by their clini-
cians as having controlled or partly controlled asthma.
Exacerbations and hospitalizations are indicative of poor
asthma control and are associated with a risk of future
exacerbations and hospitalizations [17]. Uncontrolled se-
vere asthma patients are at a high risk of exacerbations and
hospitalizations, and often have impaired quality-of-life
[4]. Clinical studies of omalizumab added to current
asthma therapy demonstrated that omalizumab reduced
the frequency of exacerbations while improving lung func-
tion and asthma symptoms. Healthcare utilization was also
reduced in these patients with uncontrolled severe allergic
asthma [7e12]. Identification of omalizumab-eligible pa-
tients in Italy and Germany who remain inadequately
controlled on current treatment could allow adjunctive
omalizumab therapy to be initiated, which may have
beneficial effects in these patients.
Omalizumab is an expensive medication, with annual
acquisition costs estimated to be V11,634 to V16,766
[18,19]. In Germany and Italy, reimbursement policies have
been implemented to balance economic costs with potential
treatment benefits. In both countries, patients receiving
omalizumab are required to be inadequately controlled on
standard asthma therapies (i.e. ICS and LABAs), consistent
with EU labelling [6]. Omalizumab is fully reimbursed in both
Germany and Italy provided that it is used in accordancewith
strict criteria, generally consistent with those set out in the
EU label. In addition, in Italy, omalizumab can only be pre-
scribed by hospital-based physicians. These requirements
help to ensure that omalizumab is prescribed cost effectively
by restricting its use to patients with unmet needs that
cannot be addressed with less expensive options. These
policies may have helped to prevent the use of omalizumab
when lower cost options would have been sufficient to meet
patients’ treatment needs. However, our results suggest that
omalizumab may actually be underutilized in Germany and
Italy. For patients who require additional therapy beyond ICS
andLABAs, several studies have indicated that omalizumab is
a cost-effective option [19e23].
Our study has a number of limitations. Firstly, the audit
was based on retrospective collection of data from patient
medical records. Patient selection was at the discretion of
the treating physician, and indications for treatment vary
between the two countries. Further, patients being treated
with medium-dose ICS (and a LABA) were included within
the Italy patient sample due to the low proportion of pa-
tients originally captured in Italy on high-dose ICS and
LABA; this proportion was not felt to be a true reflection of
the number of patients actually receiving high-dose ICS and
LABA. However, exact ICS doses for patients receiving
medium-dose ICS were not captured, and we have there-
fore assumed that ICS doses were being underestimated.
Current treatment data were collected for patients seen by
the treating physician in the last 3 months to allow
assessment of whether the patient would be eligible for
56 R. Buhl et al.omalizumab treatment; longer-term patient history was not
collected.
In conclusion, the results of this study indicate that a
significant number of patients with partly controlled/un-
controlled severe allergic asthma in Italy and Germany are
eligible for omalizumab but are not receiving it. Despite
proven benefits in severe allergic asthma patients,
adjunctive omalizumab therapy is underutilized, partly due
to inadequate referral and testing, leading to asthma
remaining uncontrolled in large numbers of patients who
may benefit from treatment. The extrapolation of these
results to a national level estimate that over 9000 patients
in Italy and Germany are potentially eligible for omalizu-
mab treatment; these eligible patients are in addition to
those already receiving treatment with omalizumab.
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